Advertisement

History of Multiple Myeloma

  • Robert A. KyleEmail author
  • David P. Steensma
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 183)

Abstract

Multiple Myeloma has been recognized since Ancient Times. The first well-documented case was reported in 1844 by Samuel Solly. The most commonly recognized case is that of Thomas Alexander McBean, a highly respectable tradesman from London in 1850. Mr. McBean excreted a large amount of protein that was described by Henry Bence Jones in the middle of the 19th century. Jones was a well-known physician and made many contributions to medicine. One of the best known cases of multiple myeloma was that of Dr. Loos that was reported by Otto Kahler. The recognition of plasma cells and subsequently their product, a monoclonal protein has been described in detail. The authors have reviewed the treatment of multiple myeloma including the novel agents, thalidomide, bortezomib and lenalidomide.

Keywords

Multiple Myeloma Myeloma Patient Orange Peel Monoclonal Protein Bence Jones Protein 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Adams W (1872) Mollities ossium. Trans Pathol Soc Lond 23:186–187Google Scholar
  2. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S, Elliott PJ (1999) Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 59:2615–2622PubMedGoogle Scholar
  3. Alexanian R, Haut A, Khan AU, Lane M, McKelvey EM, Migliore PJ, Stuckey WJ Jr, Wilson HE (1969) Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA 208:1680–1685PubMedCrossRefGoogle Scholar
  4. Alwall N (1947) Urethane and stilbamidine in multiple myeloma: report on two cases. Lancet 2:388–389PubMedCrossRefGoogle Scholar
  5. Arinkin MI (1929) Die intravitale Untersuchungsmethodik des Knochenmarks. Folia Haematologie 38:233–240Google Scholar
  6. Barlogie B, Alexanian R, Dicke KA, Zagars G, Spitzer G, Jagannath S, Horwitz L (1987) High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood 70:869–872PubMedGoogle Scholar
  7. Bayne-Jones S, Wilson DW (1922) Immunological reactions of Bence Jones proteins. II. Differences between Bence Jones proteins from various sources. Bull Johns Hopkins Hosp 33:119–125Google Scholar
  8. Bayrd ED, Heck FJ (1947) Multiple myeloma: a review of eighty-three proved cases. JAMA 133:147–157Google Scholar
  9. Bence Jones H (1842) On gravel, calculus and gout; chiefly an application of Professor Liebig’s physiology to the prevention and cure of these diseases. Taylor & Walton, LondonGoogle Scholar
  10. Bence Jones H (1845) On the state in which the uric acid exists in the urine. R. Kinder, LondonGoogle Scholar
  11. Bence Jones H (1847) Chemical pathology. Lancet 2:88–92CrossRefGoogle Scholar
  12. Bence Jones H (1848) On the new substance occurring in the urine of a patient with mollities ossium. Philos Trans R Soc Lond 138:55–62CrossRefGoogle Scholar
  13. Bence Jones H (1870) The life and letters of Faraday. J. B. Lippincott, PhiladelphiaGoogle Scholar
  14. Bence Jones H (1929) An autobiography (with elucidations at later dates by his son, A.B. Bence Jones). Crusha & Sons, London (privately printed)Google Scholar
  15. Bergsagel DE, Sprague CC, Austin C, Griffith KM (1962) Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma. IV. L-Phenylalanine mustard (NSC-8806). Cancer Chemother Rep 21:87–99PubMedGoogle Scholar
  16. Blokhin N, Larionov L, Perevodchikova N, Chebotareva L, Merkulova N (1958) Clinical experiences with sarcolysin in neoplastic diseases. Ann NY Acad Sci 68:1128–1132PubMedCrossRefGoogle Scholar
  17. Cajal SR (1896) Estudios histologicos sobre los tumores epiteliales. Rev Trimest Microgr 1:83–111Google Scholar
  18. Capasso LL (2005) Antiquity of cancer. Int J Cancer 113:2–13PubMedCrossRefGoogle Scholar
  19. Case DC Jr, Lee DJ III, Clarkson BD (1977) Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol. Am J Med 63:897–903PubMedCrossRefGoogle Scholar
  20. Ciechanover A (1994) The ubiquitin-proteasome proteolytic pathway. Cell 79:13–21PubMedCrossRefGoogle Scholar
  21. D’Amato RJ, Loughnan MS, Flynn E, Folkman J (1994) Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91:4082–4085PubMedCrossRefGoogle Scholar
  22. Day WH (1870) On the hypophosphites of iron, quinine, and strychnia in cases of general debility and nervous exhaustion. Trans Clin Soc Lond 3:1–7Google Scholar
  23. Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, San Miguel J, Hellmann A, Facon T, Foa R, Corso A, Masliak Z, Olesnyckyj M, Yu Z, Patin J, Zeldis JB, Knight RD (2007) Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 357:2123–2132PubMedCrossRefGoogle Scholar
  24. Edelman GM, Gally JA (1962) The nature of Bence-Jones proteins. Chemical similarities to polypetide chains of myeloma globulins and normal gamma-globulins. J Exp Med 116:207–227PubMedCrossRefGoogle Scholar
  25. Fefer A, Cheever MA, Greenberg PD (1986) Identical-twin (syngeneic) marrow transplantation for hematologic cancers. J Natl Cancer Inst 76:1269–1273PubMedGoogle Scholar
  26. Felter HW, Lloyd JU (1898–1900) King’s American dispensatory. Ohio Valley Co, CincinattiGoogle Scholar
  27. Fleischer R (1880) Ueber das Vorkommen des sogenannten Bence Jones’ schen Eiweisskorpers im normalen Knochenmark. Arch Pathol Anat Physiol Klin Med 80:842–849Google Scholar
  28. Gahrton G, Tura S, Flesch M, Gratwohl A, Gravett P, Lucarelli G, Michallet M, Reiffers J, Ringden O, van Lint MT et al (1987) Bone marrow transplantation in multiple myeloma: report from the European Cooperative Group for Bone Marrow Transplantation. Blood 69:1262–1264PubMedGoogle Scholar
  29. Geschickter CF, Copeland MM (1928) Multiple myeloma. Arch Surg 16:807–863Google Scholar
  30. Gestsdottir H, Eyjolfsson GI (2005) Myeloma in an archaeological skeleton from Hofstadir in Myvatnssveit. Laeknabladid 91:505–509PubMedGoogle Scholar
  31. Grabar P, Williams CA (1953) Method permitting the combined study of the electrophoretic and the immunochemical properties of protein mixtures; application to blood serum. Biochim Biophys Acta 10:193–194PubMedCrossRefGoogle Scholar
  32. Grabstald H, Golbey R (1965) Clinical experiences with thalidomide in patients with cancer. Clin Pharmacol Ther 6:298–302PubMedGoogle Scholar
  33. Hanna F (2005) Multiple myelomas in cats. J Feline Med Surg 7:275–287PubMedCrossRefGoogle Scholar
  34. Harley JB, Ramanan SV, Kim I, Thiagarajan PV, Chen JH, Gomez R, Koppel D, Hyde F, Gustke S, Krall J (1972) The cyclic use of multiple alkylating agents in multiple myeloma. W V Med J 68:1–3PubMedGoogle Scholar
  35. Harley JB, Pajak TF, McIntyre OR, Kochwa S, Cooper MR, Coleman M, Cuttner J (1979) Improved survival of increased-risk myeloma patients on combined triple-alkylating-agent therapy: a study of the CALGB. Blood 54:13–22PubMedGoogle Scholar
  36. Heller JD (1846) Die mikroscopisch-chemisch-pathologische untersuchung. Braumuller & Seidel, ViennaGoogle Scholar
  37. Heremans JF (1959) Immunochemical studies on protein pathology. The immunoglobulin concept. Clin Chim Acta 4:639–646PubMedCrossRefGoogle Scholar
  38. Herrick JB, Hektoen L (1894) Myeloma: report of a case. Med News, Philadelphia 65:239–242Google Scholar
  39. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, Anderson KC (2001) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61:3071–3076PubMedGoogle Scholar
  40. Holland JR, Hosley H, Scharlau C, Carbone PP, Frei E III, Brindley CO, Hall TC, Shnider BI, Gold GL, Lasagna L, Owens AH Jr, Miller SP (1966) A controlled trial of urethane treatment in multiple myeloma. Blood 27:328–342PubMedGoogle Scholar
  41. Hoogstraten B, Sheehe PR, Cuttner J, Cooper T, Kyle RA, Oberfield RA, Townsend SR, Harley JB, Hayes DM, Costa G, Holland JF (1967) Melphalan in multiple myeloma. Blood 30:74–83PubMedGoogle Scholar
  42. Ishizaka K, Ishizaka T, Hornbrook MM (1966) Physicochemical properties of reaginic antibody. V. correlation of reaginic activity with gamma-E-globulin antibody. J Urol 97:840–853Google Scholar
  43. Kahler O (1889) Zur symptomatologie des multiplen myeloms: Beobachtung von Albumosurie. Prager Med Wochenschr (Prague) 14:45Google Scholar
  44. Korngold L, Lipari R (1956) Multiple myeloma proteins. III. The antigenic relationship of Bence Jones proteins to normal gammaglobulin and multiple myeloma serum proteins. Cancer 9:262–272PubMedCrossRefGoogle Scholar
  45. Kühne (1883) Ueber Hemialbumose im Harn. Z Biol 19:209–227Google Scholar
  46. Kunkel HG, Tiselius A (1951) Electrophoresis of proteins on filter paper. J Gen Physiol 35:89–118PubMedCrossRefGoogle Scholar
  47. Kyle RA (1978) Monoclonal gammopathy of undetermined significance. Natural history in 241 cases. Am J Med 64:814–826PubMedCrossRefGoogle Scholar
  48. Kyle RA (2000) Multiple myeloma: an odyssey of discovery. Br J Haematol 111:1035–1044PubMedCrossRefGoogle Scholar
  49. Kyle RA (2001) Henry Bence Jones — physician, chemist, scientist and biographer: a man for all seasons. Br J Haematol 115:13–18PubMedCrossRefGoogle Scholar
  50. Lee BJ, Sahakian G, Clarkson BD, Krakoff IH (1974) Proceedings: combination chemotherapy of multiple myeloma with alkeran, cytoxan, vincristine, prednisone, and BCNU. Cancer 33:533–538PubMedCrossRefGoogle Scholar
  51. Lenz W (1962) Thalidomide and congenital abnormalities. Lancet 1:45CrossRefGoogle Scholar
  52. Lerner AB, Watson CJ (1947) Studies of cryoglobulins; unusual purpura associated with the presence of a high concentration of cryoglobulin (cold precipitable serum globulin). Am J Med Sci 214:410–415PubMedCrossRefGoogle Scholar
  53. Longsworth AB, Shedlovsky T, MacInnes DA (1939) Electrophoretic patterns of normal and pathological human blood serum and plasma. J Exp Med 70:399–413PubMedCrossRefGoogle Scholar
  54. Macintyre W (1850) Case of mollities and fragilitas ossium, accompanied with urine strongly charged with animal matter. Med Chir Trans 33:211–232PubMedGoogle Scholar
  55. Marschalko T (1895) Ueber die sogenannten plasmazellen, ein Beitrage zur Kenntniss der Herkunft der entzundlichen infiltrationszellen. Arch Dermatol Syph 30:241CrossRefGoogle Scholar
  56. Mass RE (1962) A comparison of the effect of prednisone and a placebo in the treatment of multiple myeloma. Cancer Chemother Rep 16:257–259PubMedGoogle Scholar
  57. McIntyre OR, Pajak TF, Kyle RA, Cornwell GG, Leone L (1985) Response rate and survival in myeloma patients receiving prednisone alone. Med Pediatr Oncol 13(5):239–243Google Scholar
  58. McElwain TJ, Powles RL (1983) High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet 2:822–824PubMedCrossRefGoogle Scholar
  59. Morse D, Dailey RC, Bunn J (1974) Prehistoric multiple myeloma. Bull New York Acad Med 50:447–458Google Scholar
  60. Myeloma Trialists’ Collaborative Group (1998) Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. J Clin Oncol 16:3832–3842Google Scholar
  61. Nerlich AG, Rohrbach H, Bachmeier B, Zink A (2006) Malignant tumors in two ancient populations: an approach to historical tumor epidemiology. Oncol Rep 16:197–202PubMedGoogle Scholar
  62. Nothnagel H (1893) Hofrath Otto Kahler. Wien Klin Wochenschr (Wien) 6:79–80Google Scholar
  63. Obituary (1873). Henry Bence Jones, M.D., F.R.C.P., F.R.S. Med Times Gaz 1:505Google Scholar
  64. Olson KB, Hall TC, Horton J, Khung CL, Hosley HF (1965) Thalidomide (N-Phthaloylglutamimide) in the treatment of advanced cancer. Clin Pharmacol Ther 6:292–297PubMedGoogle Scholar
  65. Orlowski RZ, Eswara JR, Lafond-Walker A, Grever MR, Orlowski M, Dang CV (1998) Tumor growth inhibition induced in a murine model of human Burkitt’s lymphoma by a proteasome inhibitor. Cancer Res 58:4342–4348PubMedGoogle Scholar
  66. Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC, Baldwin AS, Stahl S, Adams J, Esseltine DL, Elliott PJ, Pien CS, Guerciolini R, Anderson JK, Depcik-Smith ND, Bhagat R, Lehman MJ, Novick SC, O’Connor OA, Soignet SL (2002) Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 20:4420–4427PubMedCrossRefGoogle Scholar
  67. Osserman EF, DiRe LB, DiRe J, Sherman WH, Hersman JA, Storb R (1982) Identical twin marrow transplantation in multiple myeloma. Acta Haematol 68:215–223PubMedCrossRefGoogle Scholar
  68. Perlzweig WA, Delrue G, Geschicter C (1928) Hyperproteinemia associated with multiple myelomas: report of an unusual case. JAMA 90:755–757Google Scholar
  69. Peters GA, Horton BT (1941) Allergic purpura with special reference to hypersensitiveness to cold. Mayo Clin Proc 16:631–636Google Scholar
  70. Putnam FW (1993) Henry Bence Jones: the best chemical doctor in London. Perspect Biol Med 36:565–579PubMedGoogle Scholar
  71. Rajkumar SV, Hayman SR, Lacy MQ, Dispenzieri A, Geyer SM, Kabat B, Zeldenrust SR, Kumar S, Greipp PR, Fonseca R, Lust JA, Russell SJ, Kyle RA, Witzig TE, Gertz MA (2005) Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 106:4050–4053PubMedCrossRefGoogle Scholar
  72. Richardson PG, Schlossman RL, Weller E, Hideshima T, Mitsiades C, Davies F, LeBlanc R, Catley LP, Doss D, Kelly K, McKenney M, Mechlowicz J, Freeman A, Deocampo R, Rich R, Ryoo JJ, Chauhan D, Balinski K, Zeldis J, Anderson KC (2002) Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100:3063–3067PubMedCrossRefGoogle Scholar
  73. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609–2617 [see comment]PubMedCrossRefGoogle Scholar
  74. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel JF, Blade J, Boccadoro M, Cavenagh J, Dalton WS, Boral AL, Esseltine DL, Porter JB, Schenkein D, Anderson KC (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352:2487–2498PubMedCrossRefGoogle Scholar
  75. Richardson PG, Blood E, Mitsiades CS, Jagannath S, Zeldenrust SR, Alsina M, Schlossman RL, Rajkumar SV, Desikan KR, Hideshima T, Munshi NC, Kelly-Colson K, Doss D, McKenney ML, Gorelik S, Warren D, Freeman A, Rich R, Wu A, Olesnyckyj M, Wride K, Dalton WS, Zeldis J, Knight R, Weller E, Anderson KC (2006) A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 108:3458–3464PubMedCrossRefGoogle Scholar
  76. Rosenbloom J (1919) An appreciation of Henry Bence Jones, M.D., F.R.S. (1814-1873). Ann Med Hist 2:262–264Google Scholar
  77. Rosenfeld L (1987) Henry Bence Jones (1813–1873): the best “chemical doctor” in London. Clin Chem 33:1687–1692PubMedGoogle Scholar
  78. Rosenthal N, Vogel P (1938) Value of the sternal puncture in the diagnosis of multiple myeloma. Mt Sinai J Med 4:1001–1019Google Scholar
  79. Rothschild BM, Hershkovitz I, Dutour O (1998) Clues potentially distinguishing lytic lesions of multiple myeloma from those of metastatic carcinoma. Am J Phys Anthropol 105:241–250PubMedCrossRefGoogle Scholar
  80. Rowe DS, Fahey JL (1965) A new class of human immunoglobulins. I. A unique myeloma protein. J Exp Med 121:171–184PubMedCrossRefGoogle Scholar
  81. Salmon SE, Shadduck RK, Schilling A (1967) Intermittent high-dose prednisone (NSC-10023) therapy for multiple myeloma. Cancer Chemother Rep 51:179–187PubMedGoogle Scholar
  82. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeddis J, Barlogie B (1999) Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341:1565–1571 [see comment] [erratum appears in N Engl J Med 3 Feb 2000; 342(5):364]PubMedCrossRefGoogle Scholar
  83. Solly S (1844) Remarks on the pathology of mollities ossium with cases. Med Chir Trans 27:435–461PubMedGoogle Scholar
  84. Steensma DP, Kyle RA (2007) A history of the kidney in plasma cell disorders. Contrib Nephrol 153:5–24PubMedCrossRefGoogle Scholar
  85. Steinbock T (1976) Paleopathological diagnosis and interpretation. CC Thomas, SpringfieldGoogle Scholar
  86. Stephens JL (1994) Arrowroot — Maranta arundinacea L. In: Fact Sheet HS-542. A series of the Horticultural Sciences Department, Florida Cooperative Extension Service, Institute of Food and Agricultural Services, University of Florida, GainsvilleGoogle Scholar
  87. Thomas ED, Lochte HL Jr, Lu WC, Ferrebee JW (1957) Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N Engl J Med 257:491–496PubMedCrossRefGoogle Scholar
  88. Tiselius A (1937a) Electrophoresis of serum globulin. II. Electrophoretic analysis of normal and immune sera. Biochem J 31:1464–1477PubMedGoogle Scholar
  89. Tiselius A (1937b) A new apparatus for electrophoretic analysis of colloidal mixtures. T Faraday Soc 33:524CrossRefGoogle Scholar
  90. Tiselius A, Kabat EA (1939) Electrophoretic study of immune sera and purified antibody preparation. J Exp Med 69:119–131PubMedCrossRefGoogle Scholar
  91. von Behring EA, Kisato S (1890) Ueber das Zustandekommen der Diphtherie-Immunitat und der Tetanus-Immunitat bei Theieren. Dtsch Med Wochenschr 49:1113–1114Google Scholar
  92. Waldenstrom J (1960–1961) Studies on conditions associated with disturbed gamma globulin formation (gammopathies). Harvey Lect 56:211–231Google Scholar
  93. Waldeyer W (1875) Ueber bindegewebszellen. Arch Microbiol Anat 11:176–194CrossRefGoogle Scholar
  94. Weber H (1867) Mollities ossium, doubtful whether carcinomatous or syphilitic. Trans Pathol Soc Lond 23:186–187Google Scholar
  95. Weber FP (1898) General lymphadenomatosis of bones, one form of ‘multiple myeloma’. J Pathol 5:59–64CrossRefGoogle Scholar
  96. Weber FP, Hutchinson R, Macleod JJR (1903) Multiple myeloma (myelomatosis), with Bence-Jones protein in the urine (myelopathic albumosuria of Bradshaw, Kahler’s disease). Am J Med Sci 126:644–665CrossRefGoogle Scholar
  97. Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, Siegel D, Borrello I, Rajkumar SV, Chanan-Khan AA, Lonial S, Yu Z, Patin J, Olesnyckyj M, Zeldis JB, Knight RD (2007) Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 357:2133–2142PubMedCrossRefGoogle Scholar
  98. Wells C (1964) Two mediaeval cases of malignant disease. BMJ 1:1611–1612PubMedGoogle Scholar
  99. Wintrobe MM, Buell MV (1933) Hyperproteinemia associated with multiple myeloma, with report of a case in which an extraordinary hyperproteinemia was associated with thrombosis of the retinal veins and symptoms suggesting Raynaud’s disease. Bull Johns Hopkins Hosp 52:156–165Google Scholar
  100. Wright JH (1900) A case of multiple myeloma. Trans Assoc Am Physician 15:137–147Google Scholar
  101. Zink A, Rohrbach H, Szeimies U, Hagedorn HG, Haas CJ, Weyss C, Bachmeier B, Nerlich AG (1999) Malignant tumors in an ancient Egyptian population. Anticancer Res 19:4273–4277PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2011

Authors and Affiliations

  1. 1.Department of Medicine, Division of HematologyMayo ClinicRochesterUSA

Personalised recommendations